Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative
EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501
2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP operating income outlook increased for underlying operational performance, offset by increased IPR&D:
*IPR&D impact is presented due to uncertainty of the future occurrence and timing of these transactions
TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026.
Richard Francis, Teva's President and CEO, said: “Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come. The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position. Together, these achievements represent how we are delivering sustained innovative growth and translating that growth into greater profitability, with our three key innovative brands collectively growing 33% in local currency to approximately $1.1 billion year-over-year. This performance, together with continued margin expansion and cash flow generation, gives us the confidence to raise our 2026 revenue outlook for all three brands.”
Mr. Francis added: “At the same time, we are continuously building the next phase of sustainable growth at Teva. The U.S. launch of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam, anti-IL-15 and our broader late-stage pipeline supports our ambition to deliver at least five potential innovative launches over five years. Our return to investment grade and debt refinancing reflect our strengthened financial position.”
In the third quarter of 2026 and into October 2026, Teva continued to execute on the four pillars of its Pivot to Growth strategy:
Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Strong performance across all three brands supports increased 2026 revenue outlooks of these products and continues to shift Teva’s portfolio toward innovative medicines. The FDA approval and U.S. launch of WELTRUZA further expand Teva’s long-acting injectable schizophrenia portfolio and builds on the commercial momentum established by UZEDY.
Teva continued to advance a differentiated late-stage pipeline across neuroscience and immunology. The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-‘408) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year. Together with the acquisition of BXCL-501 (dexmetomidine sublingual film) from BioXcel Therapeutics, these milestones expand Teva’s capabilities in areas of significant unmet need and support its ambition to deliver a sustained cadence of potential launches.
Teva continues to strengthen its global generics business through an increased focus on complex generics and biosimilars. While global generics revenues declined primarily due to lower revenues of lenalidomide capsules (a generic version of Revlimid) in the U.S., revenues from biosimilars continued to expand. Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.
Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including ~two-thirds expected to be realized in 2026. At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile. During Q3 2026, Moody’s and S&P upgraded Teva to investment grade, following Fitch’s earlier upgrade; and Teva refinanced ~$4.9 billion of debt. All these reflect Teva's goal to achieve two times debt leverage by the end of 2027.
Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY and UZEDY.
Exchange ratemovements in the third quarter of 2026, net of hedging effects, positively impacted revenues by $5 million, compared to the third quarter of 2025.
Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6% compared to $2,304 million in the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026, an increase of 4% compared to $2,475 million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in the third quarter of 2026, compared to 55.3% in the third quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid).
Research and Development (R&D) expenses, net in the third quarter of 2026, were $297 million, an increase of 16% compared to $256 million in the third quarter of 2025. This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline. Our R&D expenses, net in the third quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years.
Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709 million, an increase of 8% compared to the third quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, and other innovative product launch preparation activities in our U.S. segment.
General and Administrative (G&A) expensesin the third quarter of 2026 were $298 million, a decrease of 6% compared to the third quarter of 2025.
Other Income in the third quarter of 2026 was $68 million, compared to other loss of $7 million in the third quarter of 2025, mainly related to a capital gain from the sale of a property in Europe.
Operating Incomewas $714 million in the third quarter of 2026, compared to an operating income of $882 million in the third quarter of 2025. Operating Income as a percentage of revenues was 16.2% in the third quarter of 2026, compared to 19.7% in the third quarter of 2025. This decrease was mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies, partially offset by an increase in gross profit. Non-GAAP operating income in the third quarter of 2026 was $1,393 million representing a non-GAAP operating margin of 31.7% compared to $1,294 million representing 28.9%, respectively, in the third quarter of 2025. This increase in non-GAAP operating margin in the third quarter of 2026 was mainly due to higher gross profit margin as described above.
Exchange rate movements in the third quarter of 2026, net of hedging effects, had a negative impact of $2 million on our operating income and non-GAAP operating income compared to the third quarter of 2025.
Financial expenses, net in the third quarter of 2026, were $414 million, mainly comprised of a loss of $224 million on extinguishment of debt and net interest expenses of $174 million. In the third quarter of 2025, financial expenses, net were $237 million, mainly comprised of net interest expenses of $209 million.
In the third quarter of 2026, we recognized a tax expense of $66 million on pre- tax income of $300 million. In the third quarter of 2025, we recognized a tax expense of $214 million on pre-tax income of $646 million.
Ourtax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%, compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax rate in the third quarter of 2026 were mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the third quarter of 2025 were mainly affected by changes in deferred tax balances due to statutory tax rate changes and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities.
Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.
Net incomeattributable to Teva and diluted earnings per sharein the third quarter of 2026 were $233 million and $0.20, respectively, compared to net income attributable to Teva and diluted earnings per share of $433 million and $0.37, respectively, in the third quarter of 2025. This decrease was mainly due to lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2026 were $1,013 million and $0.86, respectively, compared to $910 million and $0.78, respectively, in the third quarter of 2025.
Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of 7%, compared to $1,394 million in the third quarter of 2025.
As of September 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,195 million shares and 1,184 million shares, respectively.
Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were $780 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items:
We believe that excluding such items facilitates investors’ understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods.
For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow generated from operating activities during the third quarter of 2026 was $241 million compared to $369 million in the third quarter of 2025. The lower cash flow generated from operating activities in the third quarter of 2026 resulted mainly from the timing of sales and collections, partially offset by lower legal settlement payments.
During the third quarter of 2026, we generated free cash flow of $495 million, which we define as comprising: $241 million in cash flow generated from operating activities, $327 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $47 million of proceeds from the sale of businesses and long-lived assets, partially offset by $120 million in cash used for capital investments. During the third quarter of 2025, we generated free cash flow of $515 million, which we define as comprising $369 million in cash flow generated from operating activities, $274 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $8 million of proceeds from the sale of businesses and long-lived assets, partially offset by $136 million in cash used for capital investments. The decrease in the third quarter of 2026 resulted mainly from lower cash flow generated from operating activities, as discussed above, partially offset by higher proceeds from the sale of businesses and long-lived assets.
As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $256 million of exchange rate fluctuations. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. The portion of total debt classified as short-term as of September 30, 2026 was 24% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of September 30, 2026 and December 31, 2025. Our average debt maturity was approximately 6.3 years as of September 30, 2026, compared to 5.6 years as of December 31, 2025.
In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change.
The following table presents revenues, expenses and profit for our United States segment for the three months ended September 30, 2026 and 2025:
_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5% as applicable.
Revenues from our United States segment in the third quarter of 2026 were $1,870 million, a decrease of 11% compared to the third quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid), partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY, and UZEDY.
The following table presents revenues for our United States segment by major products and activities for the three months ended September 30, 2026 and 2025:
Generic products(including biosimilar products) revenues in our United States segment in the third quarter of 2026 were $718 million, a decrease of 39% compared to the third quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products and from recently launched generic products.
Among the most significant generic products we sold in the United States in the third quarter of 2026 were epinephrine injectable solution (a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to Rituxan), and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total prescriptions were approximately 227 million (based on trailing twelve months), representing 5.8% of total U.S. generic prescriptions, compared to approximately 261 million (based on trailing twelve months), representing 6.7% of total U.S. generic prescriptions in the third quarter of 2025, all according to IQVIA data.
On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab- adet) as a biosimilar to Xgeva (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.
AJOVYrevenues in our United States segment in the third quarter of 2026 were $138 million, an increase of 88% compared to the third quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the third quarter of 2026, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 32.8% out of the subcutaneous injectable anti-CGRP class, compared to 32.2% in the third quarter of 2025.
AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the third quarter of 2026 were $727 million, an increase of 21%, compared to the third quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, which is additional to the twice-daily AUSTEDO.
UZEDY(risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2026 were $85 million, an increase of 96% compared to the third quarter of 2025, mainly due to growth in volume.
On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the European Medicines Agency accepted Teva’s Marketing Authorization Application for olanzapine LAI (TEV-’749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.
BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2026 were $30 million, a decrease of 15% compared to the third quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products.
COPAXONE revenues in our United States segment in the third quarter of 2026 were $58 million, a decrease of 8% compared to the third quarter of 2025.
Gross profitfrom our United States segment in the third quarter of 2026 was $1,403 million, a decrease of 3%, compared to the third quarter of 2025.
Gross profit margin for our United States segment in the third quarter of 2026 increased to 75.0%, compared to 69.1% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid).
Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.
Profit from our United States segment in the third quarter of 2026 was $791 million, a decrease of 15% compared to $927 million in the third quarter of 2025. This decrease was mainly due to higher S&M expenses and lower gross profit, as discussed above.
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2026 and 2025:
_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable.
Revenues from our Europe segment in the third quarter of 2026 were $1,319 million, an increase of 7% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This increase was mainly due to higher revenues from generic products, higher proceeds from the sale of certain product rights, and higher revenues from AJOVY.
In the third quarter of 2026, revenues were negatively impacted by exchange rate fluctuations of $7 million, net of hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $17 million from a positive hedging impact, compared to $6 million in the third quarter of 2025, which are included in “Other” in the table below.
The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2026 and 2025:
_______________________ * Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.
Generic productsrevenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2026 were $1,033 million, an increase of 5% compared to the third quarter of 2025. In local currency terms, revenues increased by 7%, mainly due to higher sales of generic and OTC products, including from recently launched products.
AJOVYrevenues in our Europe segment in the third quarter of 2026 were $84 million, an increase of 28% compared to the third quarter of 2025. In local currency terms revenues increased by 29% mainly due to higher volumes.
COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38 million, a decrease of 12% compared to the third quarter of 2025. In local currency terms revenues decreased by 11%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.
Respiratory products revenues in our Europe segment in the third quarter of 2026 were $54 million, an increase of 3% compared to the third quarter of 2025. In local currency terms, revenues increased by 4%, mainly due to higher volumes as a result of increased supply.
Gross profitfrom our Europe segment in the third quarter of 2026 was $757 million, an increase of 14% compared to the third quarter of 2025. Gross profit margin for our Europe segment in the third quarter of 2026 increased to 57.4%, compared to 53.9% in the third quarter of 2025. This increase was mainly due to higher proceeds from the sale of certain product rights and a positive impact from hedging activities.
Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the third quarter of 2026 was $420 million, an increase of 39%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.
Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets.
As of the date of this Quarterly Report on Form 10-Q, sustained conflict between Russia and Ukraine and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. In September 2026, a warehouse that we share with other pharmaceutical companies in Ukraine was damaged, and, as of the date of this Quarterly Report on Form 10-Q, operations at this warehouse resumed. The impact of this conflict on our International Markets segment in the third quarter of 2026 was immaterial.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2026 and 2025:
_______________________ * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable.
Revenues from our International Markets segment in the third quarter of 2026 were $592 million, an increase of 6% compared to the third quarter of 2025. In local currency terms, revenues increased by 4% compared to the third quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO.
In the third quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $13 million, including hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $7 million from a positive hedging impact, compared to $2 million in the third quarter of 2025, which are included in “Other” in the table below.
The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2026 and 2025:
_______________________*Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.
Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the third quarter of 2026 were $407 million, a decrease of 3% compared to the third quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower revenues from generic and OTC products in certain markets including Ukraine.
AJOVYrevenues in our International Markets segment in the third quarter of 2026 were $48 million, an increase of 61% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This increase was mainly due to growth in multiple markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd.
AUSTEDOrevenues in our International Markets segment in the third quarter of 2026 were $24 million, an increase of 42% compared to the third quarter of 2025. In local currency terms, revenue increased by 34% compared to the third quarter of 2025, mainly due to growth in China.
COPAXONE revenues in our International Markets segment in the third quarter of 2026 were $8 million, an increase of 8% compared to the third quarter of 2025.
Gross profit from our International Markets segment in the third quarter of 2026 was $316 million, an increase of 14% compared to the third quarter of 2025.
Gross profit margin for our International Markets segment in the third quarter of 2026 increased to 53.3%, compared to 49.8% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily attributed to higher revenues from AJOVY and AUSTEDO, partially offset by lower revenues from generic products, as discussed above.
Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.
Profitfrom our International Markets segment in the third quarter of 2026 was $125 million, an increase of 32%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.
We have other sources of revenues, primarily our distribution business in the United States to third parties through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis, and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above.
In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda
In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all.
Our revenues from Other Activities in the third quarter of 2026 were $613 million, an increase of 3% in both U.S. dollars and local currency terms, compared to the third quarter of 2025.
Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.
API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and temporary supply challenges.
Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, were $98 million in the third quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency terms compared to the third quarter of 2025, mainly due to higher demand.
$ billions, except Prior Updated Key diluted EPS or as Guidance Guidance Assumptions noted Assume growth in Revenues $16.5 - $16.85 $16.7 - $17.0 innovative products AUSTEDO ($m) 2,450 - 2,600 2,550 - 2,650 AJOVY ($m) 850 - 870 930 - 960 UZEDY ($m) 270 - 290 290 - 310 Increase of $0.05B before updating Operating Income* 3.8 - 4.0 3.8 - 3.9 guidance for $0.1B impact of acquired IPR&D charge Adjusted EBITDA* 4.23 - 4.53 4.23 - 4.43 Finance Expenses* ~$0.8 ~$0.8 Tax Rate* 20% - 23% 20% - 23% Increase of $0.08 at midpoint before updating guidance Diluted EPS* ($) 1.91 - 2.11 1.92 - 2.11 for $0.07 impact of acquired IPR&D charge Free Cash Flow* 2.0 - 2.4 2.1 - 2.4 CAPEX 0.5 0.5 Volatile swings in Foreign Exchange FX can negatively impact revenue and income
Financial guidance only assumes business development transactions closed as of November 3, 2026.
Certain items above are non-GAAP financial measures. For more information, see “Non-GAAP Financial Measures” below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
Teva will host a conference call and live webcast along with a slide presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET to discuss its third quarter 2026 financial results and overall business environment.
In order to participate, please register in advance to obtain a local or toll‐free phone number and your personal pin.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit .
Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.
This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States (“GAAP”). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” "will", “expect,” “aim”, “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe”, “outlook”, “transition” and other words and terms of similar meaning and expression in connection with any discussion of future operating financial performance or development. Important factors that could cause or contribute to such differences include risks relating to:
other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.“ Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Consolid… Statemen… of Income (U.S. dollars in millions, except share and per share data) (Unaudit… Three Nine months months ended ended September September 30, 30, 2026 2025 2026 2025 Net $ 4,395 $ 4,480 $ 12,519 $ 12,547 revenues Cost of 1,955 2,176 5,954 6,264 sales Gross 2,440 2,304 6,565 6,282 profit Research and 297 256 1,489 746 developm… expenses Selling and 709 656 2,122 1,933 marketing expenses General and 298 317 919 920 administ… expenses Intangib… assets 24 64 54 227 impairme… Other asset impairme… 264 62 438 272 restruct… and other items Legal settleme… 202 60 504 312 and loss continge… Other loss -68 7 -96 15 (income) Operating income 714 882 1,135 1,857 (loss) Financial expenses, 414 237 854 714 net Income (loss) before 300 646 282 1,143 income taxes Income taxes 66 214 254 210 (benefit) Share in (profits) losses of * -2 * -4 associat… companie… net Net income 234 434 27 937 (loss) Net income (loss) attribut… to 1 1 1 7 redeemab… and non-rede… non-cont… interest Net income (loss) 233 433 26 930 attribut… to Teva Earnings (loss) per share Basic $ 0.20 $ 0.38 $ 0.02 $ 0.81 attribut… to Teva: Diluted $ 0.20 $ 0.37 $ 0.02 $ 0.80 Weighted average number of Basic 1,166 1,147 1,162 1,144 shares (in millions… Diluted 1,183 1,164 1,180 1,160 Non-GAAP net income attribut… to Teva 1,013 910 1,655 2,281 for diluted earnings per share:** Non-GAAP earnings per share Diluted $ 0.86 $ 0.78 $ 1.40 $ 1.97 attribut… to Teva:** Non-GAAP average number of Diluted 1,183 1,164 1,180 1,160 shares (in millions… Amounts may not add up due to rounding. * Represen… an amount less than $0.5 million. ** See reconcil… attached.
CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited) ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 4,085 $ 3,556 Accounts receivables, net of allowance for credit losses of $71 million and $81 million 3,837 3,709 as of September 30, 2026 and December 31, 2025, respectively. Inventories 3,173 3,179 Prepaid expenses 1,014 1,122 Other current assets 658 539 Assets held for sale 1,836 1,842 Total current assets 14,602 13,946 Deferred income taxes 2,057 2,191 Other non-current assets 269 405 Property, plant and 3,747 4,080 equipment, net Operating lease right-of-use 321 345 assets, net Identifiable intangible 3,303 3,781 assets, net Goodwill 15,742 16,000 Total assets $ 40,042 $ 40,748 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ 4,038 $ 1,820 Sales reserves and allowances 3,955 4,143 Accounts payables 2,551 2,531 Employee-related obligations 588 739 Accrued expenses 2,962 2,687 Other current liabilities 1,036 1,182 Liabilities held for sale 296 354 Total current liabilities 15,425 13,456 Long-term liabilities: Deferred income taxes 263 296 Other taxes and long-term 3,422 3,808 liabilities Senior notes and loans 12,680 14,986 Operating lease liabilities 266 288 Total long-term liabilities 16,632 19,379 Equity: Teva shareholders’ equity: 7,979 7,910 Non-controlling interests 5 4 Total equity 7,984 7,914 Total liabilities and equity $ 40,042 $ 40,748 Amounts may not add up due to rounding.
TEVA PHARMACEUTI… INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited) Three months Nine months Operating ended ended activities: September 30, 2026 2025 September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 234 434 $ 27 937 (loss) Adjustments to reconcile net income (loss) to net cash provided by operations: Depreciation and 245 249 725 742 amortization Impairment of long-lived 228 79 350 255 assets and assets held for sale Acquired in-process 23 17 785 52 research and development* Net change in operating -682 -578 -1,523 -1,647 assets and liabilities Deferred income taxes – net and 53 107 56 -76 uncertain tax positions Stock-based 38 34 121 106 compensation Loss on extinguishm… 224 - 224 - of debt Other items -53 27 -65 122 Net loss (gain) from sale of business -69 - -89 - and long-lived assets Net cash provided by (used in) 241 369 612 491 operating activities Investing activities: Beneficial interest collected in exchange for 327 274 992 932 securitized accounts receivables Purchases of property, plant and equipment -120 -136 -393 -359 and intangible assets Proceeds from sale of businesses 47 8 93 34 and long-lived assets, net Purchases of in-process -46 -12 -747 -41 research and development* Other investing 2 1 3 6 activities Net cash provided by (used in) 210 135 -52 572 investing activities Financing activities: Repayment of senior notes and loans and -4,883 -444 -4,906 -4,112 other long-term liabilities Proceeds from senior notes, net 4,845 -7 4,845 2,298 of issuance costs Purchase of shares from redeemable and - - - -38 non-redeema… non-control… interests Dividends paid to redeemable and - - - -340 non-redeema… non-control… interests Other financing 43 -2 78 1 activities Net cash provided by (used in) 6 -453 18 -2,191 financing activities Effect of exchange rate changes -27 -9 -49 31 on cash and cash equivalents Net change in cash and 430 42 529 -1,097 cash equivalents Balance of cash and cash equivalents 3,655 2,161 $ 3,556 3,300 at beginning of period Balance of cash and cash equivalents $ 4,085 2,203 $ 4,085 2,203 at end of period Non-cash financing and investing activities: Beneficial interest obtained in exchange $ 253 296 $ 859 937 for securitized accounts receivables Receivable for sale of 90 - 90 - long-lived assets * In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101). Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements.
($ in millions except per share amounts) Net income (Loss) attributable to Teva Increase (decrease) for excluded items: Amortization of purchased intangible assets Legal settlements and loss contingenci… Impairment of long-lived assets(2) Restructuri… costs(3) Equity compensation Three Contingent months Nine months considerati… ended ended Financial September September expenses(4) 30, 30, Other 2026 2025 2026 2025 Reconcilia… non-GAAP 233 433 26 930 of net items(5) 139 144 415 436 income Correspondi… 201 60 503 309 (loss) tax effects 228 79 350 255 attributab… and unusual 58 29 121 196 to Teva tax items(6) 38 34 121 106 to Non-GAAP Non-GAAP net 2 16 25 46 net income income 235 7 256 58 (loss) attributable 14 51 55 170 attributab… to Teva (134) 58 (216) (225) to Teva Non-GAAP tax 1,013 910 1,655 2,281 (Unaudited) rate(7) 16.5 % 14.7 % 22.1 % 16.0 % ────────────────────────────────────────────────────────────────────────────── GAAP diluted earnings (loss) per $ 0.20 0.37 $ 0.02 0.80 share attributable to Teva EPS 0.66 0.41 1.38 1.16 difference(… Non-GAAP diluted EPS $ 0.86 0.78 $ 1.40 1.97 attributable to Teva(8) Non-GAAP average number of 1,183 1,164 1,180 1,160 shares (in millions)(8) For the three months ended September 30, 2026, adjustments for legal settlements and loss contingenci… mainly consisted of (a) an update to the estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations in the amount of $133 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $35 million. For the nine months ended September 30, 2026, adjustments for legal settlements and loss contingenci… mainly consisted of (a) an estimated provision recorded in connection with one of the Company’s ongoing antitrust litigations in the amount of $250 million, and (b) (1) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $132 million. For the three and nine months ended September 30, 2025, adjustments of legal settlements and loss contingenci… mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $42 million and $139 million, respectivel… and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S. in the generic drug antitrust litigation in the amount of $55 million. The expense for the three and nine months ended September 30, 2026, mainly consisted of (a) impairment charges in connection with several manufacturi… facilities in Europe in the amount of $140 million and $210 million, respectivel… and (b) impairment charges in connection with the held for sale measurement of the API business (including its R&D, manufacturi… (2) and commercial activities), which includes an impact related to the expected gain from reclassific… of currency translation adjustments in the amount of $49 million and $66 million, respectivel… For the nine months ended September 30, 2025, the adjustment for impairment of long-lived assets was mainly related to intangible assets in the U.S. and Europe. In the nine months ended September 30, 2026 and 2025, Teva recorded restructuri… expenses of $121 million and $196 million, respectivel… primarily related to optimization (3) activities in connection with Teva’s Transformat… programs related to Teva’s global organization and operations mainly through headcount reduction. In the three and nine months ended September 30, 2026, Teva recorded (4) $224 million of finance expenses related to a loss on extinguishm… of debt. Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an (5) understandi… of trends in our financial results, primarily related to material litigation fees, rationaliza… of our plants, accelerated depreciation and other unusual events. Adjustments for correspondi… tax effects and unusual tax items exclusively consisted of the tax impact directly (6) attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table. Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the nine months ended September 30, 2026 was mainly affected by an unfavorable tax impact (7) of a non-deducti… acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictio… in which tax rates are different than the Israeli tax rate, and other infrequent or non-recurri… items, such as internal legal entities reorganizat… EPS difference and diluted non-GAAP EPS are calculated by dividing our (8) non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.
Reconciliation of gross profit to Non-GAAP gross profit (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in millions) 2026 2025 2026 2025 Gross profit $ 2,440 2,304 $ 6,565 6,282 Gross profit 55.5% 51.4% 52.4% 50.1% margin Increase (decrease) for excluded items: (1) Amortization of purchased 129 134 387 406 intangible assets Equity 6 6 18 17 compensation Other non-GAAP 5 32 11 101 items Non-GAAP gross $ 2,580 2,475 $ 6,981 6,807 profit Non-GAAP gross profit margin 58.7% 55.3% 55.8% 54.3% (2) (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.
Reconciliation of operating income (loss) to Non-GAAP operating income (loss) (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in millions) 2026 2025 2026 2025 Operating $ 714 882 $ 1,135 1,857 income (loss) Operating 16.2 % 19.7 % 9.1 % 14.8 % margin Increase (decrease) for excluded items: (1) Amortization of purchased 139 144 415 436 intangible assets Legal settlements and 201 60 503 309 loss contingencies Impairment of long-lived 228 79 350 255 assets Restructuring 58 29 121 196 costs Equity 38 34 121 106 compensation Contingent 2 16 25 46 consideration Loss (gain) on sale of -1 6 -5 19 business Other non-GAAP 15 45 60 149 items Non-GAAP operating $ 1,393 1,294 $ 2,724 3,373 income (loss) Non-GAAP operating 31.7 % 28.9 % 21.8 % 26.9 % margin(2) (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.
Reconcilia… of net income (loss) to adjusted EBITDA (Unaudited) Three months Nine months ended ended September 30, September 30, ($ in 2026 2025 2026 2025 millions) Net income $ 234 434 $ 27 937 (loss) Increase (decrease) for excluded items:(1) Financial 414 237 854 714 expenses Income taxes 66 214 254 210 Share in profits (losses) of § -2 § -4 associated companies –net Depreciation 106 105 311 306 Amortization 139 144 415 436 EBITDA 959 1,131 1,861 2,599 Legal settlements 201 60 503 309 and loss contingenci… Impairment of long 228 79 350 255 lived assets Restructuri… 58 29 121 196 costs Equity 38 34 121 106 compensation Contingent 2 16 25 46 considerati… Loss (Gain) on sale of -1 6 -5 19 Business Other non-GAAP 12 40 50 137 items Adjusted $ 1,496 1,394 $ 3,025 3,668 EBITDA (1) For further explanatio… refer to the footnotes under the "Reconcili… of net income (loss) attributab… to Teva to Non-GAAP net income (loss) attributab… to Teva" table. § Represents an amount of less than $0.5 million.
Reconciliation of our segment profit Three months ended to consolidated income (loss) before September 30, income taxes (U.S.$ in millions) 2026 2025 ────────────────────────────────────────────────────────────────────────────── United States profit $ 791 $ 927 Europe profit 420 303 International Markets profit 125 95 Total reportable segment profit 1,336 1,325 Profit (loss) of other activities 57 -31 Amounts not allocated to segments: Amortization 139 144 Other asset impairments, restructuring 264 62 and other items Intangible asset impairments 24 64 Legal settlements and loss 201 60 contingencies Other unallocated amounts 51 82 Consolidated operating income (loss) 714 882 Financial expenses - net 414 237 Consolidated income (loss) before income $ 300 $ 646 taxes
Nine months ended Reconciliation of our September 30, segment profit September 30, to consolidated income 2026 (loss) before income taxes (U.S.$ in millions) 2025 ────────────────────────────────────────────────────────────────────────────── United States profit $ 1,222 $ 2,143 Europe profit 1,188 996 International Markets 289 266 profit Total reportable segment 2,699 3,405 profit Profit (loss) of other 25 -32 activities Amounts not allocated to segments: Amortization 415 436 Other asset impairments, restructuring 438 272 and other items Intangible asset 54 227 impairments Legal settlements and loss 503 309 contingencies Other unallocated amounts 179 272 Consolidated operating 1,135 1,857 income (loss) Financial expenses - net 854 714 Consolidated income (loss) before income $ 282 $ 1,143 taxes
Segment revenues by major products and activities Three months ended (Unaudited) September 30, Percentage United States 2026 Change segment (U.S.$ in millions) 2025 2026-2025 ────────────────────────────────────────────────────────────────────────────── Generic products (including $ 718 $ 1,175 (39)% biosimilars) AJOVY 138 73 88 % AUSTEDO 727 601 21 % BENDEKA and TREANDA 30 35 (15)% COPAXONE 58 62 (8)% UZEDY 85 43 96 % Other 114 101 13 % Total 1,870 2,090 (11)% Three months ended Percentage September 30, Change 2026 2025 2026-2025 -U.S.$ in millions Europe segment Generic products (including OTC and $ 1,033 $ 982 5 % biosimilars) AJOVY 84 66 28 % COPAXONE 38 44 (12)% Respiratory 54 52 3 % products Other* 111 91 21 % Total 1,319 1,235 7 % *Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights Three months ended Percentage September 30, Change 2026 2025 2026-2025 -U.S.$ in millions International Markets segment Generic products (including OTC and $ 407 $ 421 (3)% biosimilars) AJOVY 48 30 61 % AUSTEDO 24 17 42 % COPAXONE 8 8 8 % Other* 105 82 28 % Total 592 557 6 % *Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights
Segment revenues by major products Nine months ended and activities September 30, (Unaudited) 2026 Percentage United States (U.S.$ in Change segment millions) 2025 2025-2026 ────────────────────────────────────────────────────────────────────────────── Generic $ 1,990 $ 2,984 (33)% products AJOVY 341 190 80 % AUSTEDO 1,963 1,492 32 % BENDEKA / 85 111 (24)% TREANDA COPAXONE 182 179 2 % UZEDY 225 136 65 % Other 321 321 § Total 5,106 5,413 (6)% § Represents an amount less than 0.5%. Nine months ended September 30, Percentage Change 2026 2025 2025-2026 -U.S.$ in millions Europe segment Generic $ 3,146 $ 3,011 4 % products AJOVY 238 195 22 % COPAXONE 127 135 (6)% Respiratory 171 162 6 % products Other* 241 223 8 % Total 3,922 3,726 5 % *Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights. Nine months ended September 30, Percentage Change 2026 2025 2025-2026 -U.S.$ in millions International Markets segment Generic $ 1,212 $ 1,298 (7)% products AJOVY 130 78 68 % AUSTEDO 63 34 82 % COPAXONE 22 25 (13)% Other* 239 199 20 % Total 1,666 1,634 2 % *Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.
Free cash flow reconciliation (Unaudited) Three months ended September 30, 2026 2025 -U.S. $ in millions Net cash provided by (used in) operating 241 369 activities Beneficial interest collected in exchange for 327 274 securitized account receivables Capital investment -120 -136 Proceeds from sale of businesses and 47 8 long-lived assets, net Free cash flow $ 495 $ 515
Free cash flow reconciliation (Unaudited) Nine months ended September 30, 2026 2025 -U.S. $ in millions Net cash provided by (used in) operating 612 491 activities Beneficial interest collected in exchange for securitized 992 932 trade receivables Capital investment -393 -359 Proceeds from sale of businesses and 93 34 long-lived assets, net Free cash flow $ 1,305 $ 1,098
Net debt reconciliation unaudited September 30, 2026 Short-term debt 4,038 Senior notes and loans 12,680 Total debt 16,718 Net of cash and cash equivalents 4,085 Net debt $ 12,633
Full text with the tables
EXHIBIT 99.1
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative
Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers
Substantial Gross Margin Expansion
COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC
ADDITION OF BXCL-501
Q3 2026 revenues of $4.4 billion
AUSTEDO
AJOVY
UZEDY
Q3 2026 Highlights:
2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP
operating income outlook increased for underlying operational performance,
offset by increased IPR&D:
*IPR&D impact is presented due to uncertainty of the future occurrence and
timing of these transactions
TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA) today reported results
for the quarter ended September 30, 2026.
Richard Francis, Teva's President and CEO, said: “Our strong third-quarter
performance is another clear demonstration
of Pivot to Growth in action and how far Teva has come. The FDA approval of
WELTRUZA has further advanced our innovative portfolio, our
recently announced biosimilars agreement with Samsung Bioepis has strengthened
our generics powerhouse and our return to investment grade
reflects the transformation of our financial position. Together, these
achievements represent how we are delivering sustained innovative
growth and translating that growth into greater profitability, with our three
key innovative brands collectively growing 33% in local
currency to approximately $1.1 billion year-over-year. This performance,
together with continued margin expansion and cash flow generation,
gives us the confidence to raise our 2026 revenue outlook for all three brands.”
Mr. Francis added: “At the same time, we are continuously building the next
phase of sustainable growth at Teva. The U.S. launch
of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam,
anti-IL-15 and our broader late-stage pipeline supports
our ambition to deliver at least five potential innovative launches over five
years. Our return to investment grade and debt refinancing
reflect our strengthened financial position.”
Pivot to Growth Strategy
In the third quarter of 2026 and into October 2026, Teva continued to execute on
the four pillars of its Pivot to Growth strategy:
Delivering on our growth engines
Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated
approximately $1.1 billion in revenues and grew
33% year-over-year in local currency. Strong performance across all three brands
supports increased 2026 revenue outlooks of these products
and continues to shift Teva’s portfolio toward innovative medicines. The FDA
approval and U.S. launch of WELTRUZA further expand
Teva’s long-acting injectable schizophrenia portfolio and builds on the
commercial momentum established by UZEDY.
Stepping up innovation
Teva continued to advance a differentiated late-stage pipeline across
neuroscience and immunology. The FDA accepted ecopipam's (EBS-101)
NDA for review, positive Phase 2a results were reported for anti-IL-15
(TEV-‘408) in Celiac disease, and the anti-IL-15 program
is planned to advance into Phase 2b development in vitiligo later this year.
Together with the acquisition of BXCL-501 (dexmetomidine
sublingual film) from BioXcel Therapeutics, these milestones expand Teva’s
capabilities in areas of significant unmet need and support
its ambition to deliver a sustained cadence of potential launches.
Sustaining our generics powerhouse
Teva continues to strengthen its global generics business through an increased
focus on complex generics and biosimilars. While global
generics revenues declined primarily due to lower revenues of lenalidomide
capsules (a generic version of Revlimid) in
the U.S., revenues from biosimilars continued to expand. Teva currently expects
more than $0.8 billion in biosimilars revenues in 2026,
reaching its original 2027 revenue objective one year early, with further
portfolio expansion supported by new collaborations, including
the recently announced agreement with Samsung Bioepis.
Focusing our business
Teva continued to transform and modernize its business through the Teva
Transformation programs, which combined with innovative product
growth potential, is expected to support the Company’s objective of achieving a
30% non-GAAP operating income margin and approximately
$700 million of net savings, by 2027 including ~two-thirds expected to be
realized in 2026. At the same time, Teva continued to maintain
disciplined capital allocation and strengthen its financial profile. During Q3
2026, Moody’s and S&P upgraded Teva to investment
grade, following Fitch’s earlier upgrade; and Teva refinanced ~$4.9 billion of
debt. All these reflect Teva's goal to achieve two
times debt leverage by the end of 2027.
Third Quarter 2026 Consolidated Results
Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in
both U.S. dollars and local currency
terms compared to the third quarter of 2025. This decrease was mainly due to
lower revenues from generic products, primarily lenalidomide
capsules (a generic version of Revlimid) in our U.S. segment, partially offset
by higher revenues from our key innovative
products, primarily AUSTEDO, AJOVY and UZEDY.
Exchange ratemovements in the third quarter of 2026, net of hedging effects,
positively impacted revenues by $5 million,
compared to the third quarter of 2025.
Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6%
compared to $2,304 million in the
third quarter of 2025. Gross profit margin was 55.5% in the third quarter of
2026, compared to 51.4% in the third quarter
of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026,
an increase of 4% compared to $2,475
million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in
the third quarter of 2026, compared to
55.3% in the third quarter of 2025. The increase in both gross profit margin and
non-GAAP gross profit margin was mainly due to a favorable
mix of products, primarily higher revenues from our key innovative products,
largely AUSTEDO, partially offset by lower revenues from
generic products, primarily lenalidomide capsules (a generic version of
Revlimid).
Research and Development (R&D) expenses, net in the third quarter of 2026, were
$297 million,
an increase of 16% compared to $256 million in the third quarter of 2025. This
increase was mainly due to higher expenses in our immunology
and neuroscience projects, as well as in our biosimilars pipeline. Our R&D
expenses, net in the third quarters of 2026 and 2025, were
also impacted by reimbursements and cost sharing from our strategic partnerships
and collaborations entered into in recent years.
Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709
million, an increase of 8% compared
to the third quarter of 2025. This increase was mainly due to promotional
activities related to our key innovative products, primarily
AUSTEDO, and other innovative product launch preparation activities in our U.S.
segment.
General and Administrative (G&A) expensesin the third quarter of 2026 were $298
million, a decrease of 6% compared
to the third quarter of 2025.
Other Income in the third quarter of 2026 was $68 million, compared to other
loss of $7 million in the third quarter
of 2025, mainly related to a capital gain from the sale of a property in Europe.
Operating Incomewas $714 million in the third quarter of 2026, compared to an
operating income of $882 million in
the third quarter of 2025. Operating Income as a percentage of revenues was
16.2% in the third quarter of 2026, compared to 19.7% in the
third quarter of 2025. This decrease was mainly due to higher tangible asset
impairments and higher legal settlements and loss contingencies,
partially offset by an increase in gross profit. Non-GAAP operating income in
the third quarter of 2026 was $1,393 million
representing a non-GAAP operating margin of 31.7% compared to $1,294 million
representing 28.9%, respectively, in the third quarter of
2025. This increase in non-GAAP operating margin in the third quarter of 2026
was mainly due to higher gross profit margin as described
above.
Exchange rate movements in the third quarter of 2026, net of hedging effects,
had a negative impact of $2 million
on our operating income and non-GAAP operating income compared to the third
quarter of 2025.
Financial expenses, net in the third quarter of 2026, were $414 million, mainly
comprised of a loss of $224 million
on extinguishment of debt and net interest expenses of $174 million. In the
third quarter of 2025, financial expenses, net were $237 million,
mainly comprised of net interest expenses of $209 million.
In the third quarter of 2026, we recognized a tax expense of $66 million on pre-
tax income of $300 million. In the third quarter of
2025, we recognized a tax expense of $214 million on pre-tax income of $646
million.
Ourtax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the
third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%,
compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax
rate in the third quarter of 2026 were mainly affected by the generation of
profits in various jurisdictions in which tax rates are different
than the Israeli tax rate and other infrequent or non-recurring items. Our tax
rate and non-GAAP tax rate in the third quarter of 2025
were mainly affected by changes in deferred tax balances due to statutory tax
rate changes and interest and inflation adjustments related
to the agreement with the Israeli Tax Authorities.
Considering the above, we expect our annual non-GAAP tax rate for 2026 to be
between 20%-23%, higher than our non-GAAP tax rate for
2025, which was 15.8%.
Net incomeattributable to Teva and diluted earnings per sharein the third
quarter
of 2026 were $233 million and $0.20, respectively, compared to net income
attributable to Teva and diluted earnings per share of $433
million and $0.37, respectively, in the third quarter of 2025. This decrease was
mainly due to lower operating income, as discussed above.
Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share
in the third quarter
of 2026 were $1,013 million and $0.86, respectively, compared to $910 million
and $0.78, respectively, in the third quarter of 2025.
Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of
7%, compared to $1,394 million in
the third quarter of 2025.
As of September 30, 2026 and 2025, the fully diluted share count for purposes of
calculating our market capitalization
was approximately 1,195 million shares and 1,184 million shares, respectively.
Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were
$780 million. Non-GAAP net income attributable
to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to
exclude the following items:
We believe that excluding such items facilitates investors’ understanding of our
business including underlying trends, thereby
improving the comparability of our business performance results between
reporting periods.
For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures
and for additional information, see the tables below
and the information included under “Non-GAAP Financial Measures.” Investors
should consider non-GAAP financial measures in
addition to, and not as replacement for, or superior to, measures of financial
performance prepared in accordance with GAAP.
Cash flow generated from operating activities during the third quarter of 2026
was $241 million compared to $369 million
in the third quarter of 2025. The lower cash flow generated from operating
activities in the third quarter of 2026 resulted mainly from
the timing of sales and collections, partially offset by lower legal settlement
payments.
During the third quarter of 2026, we generated free cash flow of $495 million,
which we define as comprising: $241
million in cash flow generated from operating activities, $327 million in
beneficial interest collected in exchange for securitized accounts
receivables (under our EU securitization program) and $47 million of proceeds
from the sale of businesses and long-lived assets, partially
offset by $120 million in cash used for capital investments. During the third
quarter of 2025, we generated free cash flow of $515 million,
which we define as comprising $369 million in cash flow generated from operating
activities, $274 million in beneficial interest collected
in exchange for securitized accounts receivables (under our EU securitization
program) and $8 million of proceeds from the sale of businesses
and long-lived assets, partially offset by $136 million in cash used for capital
investments. The decrease in the third quarter of 2026
resulted mainly from lower cash flow generated from operating activities, as
discussed above, partially offset by higher proceeds from
the sale of businesses and long-lived assets.
As of September 30, 2026, our debt was $16,718 million, compared to $16,807
million as of December 31, 2025. This
decrease was mainly due to $256 million of exchange rate fluctuations. In
addition, during the third quarter of 2026, we consummated
an early redemption of $4,678 million in aggregate principal amount of senior
notes and concurrently, issued $4,837 million
of new senior notes, net of discount and issuance costs. The portion of total
debt classified as short-term as of September 30, 2026 was
24% compared to 11% as of December 31, 2025. Our financial leverage, which is
the ratio between our debt and the sum of our debt and equity,
was 68% as of September 30, 2026 and December 31, 2025. Our average debt
maturity was approximately 6.3 years as of September 30, 2026,
compared to 5.6 years as of December 31, 2025.
Segment Results for the third quarter of 2026
United States Segment
In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda
is no longer reported under our United States segment.
This shift allows the United States segment to continue to manage its entire
product portfolio in the region, while strengthening focus
on its biopharmaceutical business, growth engines and innovation. As a result,
from that date, Anda is reported as part of the Company’s
Other Activities. Prior period amounts were recast to reflect this change.
The following table presents revenues, expenses and profit for our United States
segment for the three months ended September 30, 2026
and 2025:
Three months
ended
September 30,
2026
(U.S. $ in
millions / % of
Segment Revenues) 2025
──────────────────────────────────────────────────────────────────────────────
Revenues $ 1,870 100 % $ 2,090 100 %
Cost of sales 467 25.0 % 645 30.9 %
Gross profit 1,403 75.0 % 1,446 69.1 %
R&D expenses 196 10.5 % 161 7.7 %
S&M expenses 306 16.4 % 248 11.8 %
G&A expenses 109 5.9 % 113 5.4 %
Other § § -3 §
Segment profit* $ 791 42.3 % $ 927 44.3 %
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5% as applicable.
Revenues from our United States segment in the third quarter of 2026 were $1,870
million, a decrease of 11% compared
to the third quarter of 2025, mainly due to lower revenues from generic
products, primarily lenalidomide capsules (a generic version of
Revlimid), partially offset by higher revenues from our key innovative products,
primarily AUSTEDO, AJOVY, and UZEDY.
Revenues by Major Products and Activities
The following table presents revenues for our United States segment by major
products and activities for the three months ended September
30, 2026 and 2025:
Three months ended
September
30,
2026 Percentage
(U.S.$ in Change
millions) 2025 2026-2025
──────────────────────────────────────────────────────────────────────────────
Generic products
(including $ 718 $ 1,175 (39)%
biosimilars)
AJOVY 138 73 88%
AUSTEDO 727 601 21%
BENDEKA and 30 35 (15)%
TREANDA
COPAXONE 58 62 (8)%
UZEDY 85 43 96%
Other 114 101 13%
Total $ 1,870 $ 2,090 (11)%
Generic products(including biosimilar products) revenues in our United States
segment in the third quarter
of 2026 were $718 million, a decrease of 39% compared to the third quarter of
2025. This decrease was mainly driven by lower revenues
from lenalidomide capsules (a generic version of Revlimid) due to increased
generic competition in the U.S., partially
offset by higher revenues from our portfolio of biosimilar products and from
recently launched generic products.
Among the most significant generic products we sold in the United States in the
third quarter of 2026 were epinephrine injectable solution
(a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to
Rituxan),
and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total
prescriptions were approximately
227 million (based on trailing twelve months), representing 5.8% of total U.S.
generic prescriptions, compared to approximately 261 million
(based on trailing twelve months), representing 6.7% of total U.S. generic
prescriptions in the third quarter of 2025, all according to
IQVIA data.
On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-
adet) as a biosimilar to Xgeva
(denosumab). DEGEVMA is indicated for the prevention of bone complications in
adults with advanced cancer that has spread to the bone,
for the treatment of adults and skeletally mature adolescents with giant cell
tumor of bone, and for the treatment of hypercalcemia of
malignancy.
AJOVYrevenues in our United States segment in the third quarter of 2026 were
$138 million, an increase of 88% compared
to the third quarter of 2025, mainly due to a reduction in sales allowance as
well as growth in volume. In the third quarter of 2026,
AJOVY’s exit market share in the United States in terms of total number of
prescriptions was 32.8% out of the subcutaneous injectable
anti-CGRP class, compared to 32.2% in the third quarter of 2025.
AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the
third quarter of
2026 were $727 million, an increase of 21%, compared to the third quarter of
2025. This increase was mainly due to growth in volume and
a favorable business mix including improved net-price realization.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA
on February 17, 2023 in three doses of 6, 12 and 24
mg, and became commercially available in the U.S. in May 2023. The FDA approved
AUSTEDO XR as a one pill, once-daily treatment option
in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO
XR is a once-daily formulation indicated in adults for
tardive dyskinesia and chorea associated with Huntington’s disease, which is
additional to the twice-daily AUSTEDO.
UZEDY(risperidone) extended-release injectable suspension revenues in our United
States segment in the third quarter
of 2026 were $85 million, an increase of 96% compared to the third quarter of
2025, mainly due to growth in volume.
On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for
extended-release injectable suspension,
a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment
of schizophrenia in adults. WELTRUZA is expected to become
available in the U.S. in the coming weeks, in three different strengths (318 mg,
425 mg, 531 mg). In May 2026, the European Medicines
Agency accepted Teva’s Marketing Authorization Application for olanzapine LAI
(TEV-’749). WELTRUZA is protected in the U.S.
by four Orange Book listed patents expiring between 2033 and 2044, and in Europe
by five granted patents expiring between 2031 and 2044.
BENDEKA and TREANDA combined revenues in our United States segment
in the third quarter of 2026 were $30 million, a decrease of 15% compared to the
third quarter of 2025, mainly due to competition from
alternative therapies, as well as from branded and generic bendamustine
products.
COPAXONE revenues in our United States segment in the third quarter of 2026 were
$58 million, a decrease
of 8% compared to the third quarter of 2025.
United States Gross Profit
Gross profitfrom our United States segment in the third quarter of 2026 was
$1,403 million, a decrease of 3%, compared
to the third quarter of 2025.
Gross profit margin for our United States segment in the third quarter of 2026
increased to 75.0%, compared to 69.1%
in the third quarter of 2025. This increase was mainly due to a favorable mix of
products, primarily higher revenues from our key innovative
products, largely AUSTEDO, partially offset by lower revenues from lenalidomide
capsules (a generic version of Revlimid).
United States Profit
Profit from our United States segment consists of revenues less cost of sales,
R&D expenses, S&M expenses, G&A expenses
and other expenses (income) related to this segment. Segment profit does not
include amortization and certain other items.
Profit from our United States segment in the third quarter of 2026 was $791
million, a decrease of 15% compared to
$927 million in the third quarter of 2025. This decrease was mainly due to
higher S&M expenses and lower gross profit, as discussed
above.
Europe Segment
Our Europe segment includes the European Union, the United Kingdom and certain
other European countries.
The following table presents revenues, expenses and profit for our Europe
segment for the three months ended September 30, 2026 and
2025:
Three months
ended September
30,
2026
(U.S. $ in
millions / % of
Segment
Revenues) 2025
──────────────────────────────────────────────────────────────────────────────
Revenues $ 1,319 100 % $ 1,235 100 %
Cost of sales 562 42.6 % 570 46.1 %
Gross profit 757 57.4 % 665 53.9 %
R&D expenses 62 4.7 % 62 5.0 %
S&M expenses 211 16.0 % 225 18.2 %
G&A expenses 64 4.8 % 75 6.1 %
Other § § § §
Segment profit* $ 420 31.8 % $ 303 24.5 %
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.
Revenues from our Europe segment in the third quarter of 2026 were $1,319
million, an increase of 7% in both U.S.
dollars and local currency terms, compared to the third quarter of 2025. This
increase was mainly due to higher revenues from generic
products, higher proceeds from the sale of certain product rights, and higher
revenues from AJOVY.
In the third quarter of 2026, revenues were negatively impacted by exchange rate
fluctuations of $7 million, net of hedging effects,
compared to the third quarter of 2025. Revenues in the third quarter of 2026
included $17 million from a positive hedging impact, compared
to $6 million in the third quarter of 2025, which are included in “Other” in the
table below.
Revenues by Major Products and Activities
The following table presents revenues for our Europe segment by major products
and activities for the three months ended September
30, 2026 and 2025:
Three months ended
September
30,
2026 Percentage
(U.S.$ in Change
millions) 2025 2026-2025
──────────────────────────────────────────────────────────────────────────────
Generic products
(including OTC and $ 1,033 $ 982 5%
biosimilars)
AJOVY 84 66 28%
COPAXONE 38 44 (12)%
Respiratory 54 52 3%
products
Other* 111 91 21%
Total $ 1,319 $ 1,235 7%
_______________________
* Other revenues in the third quarters of 2026 and 2025 include the sale of
certain product rights.
Generic productsrevenues (including OTC and biosimilar products) in our Europe
segment in the third quarter of 2026
were $1,033 million, an increase of 5% compared to the third quarter of 2025. In
local currency terms, revenues increased by 7%, mainly
due to higher sales of generic and OTC products, including from recently
launched products.
AJOVYrevenues in our Europe segment in the third quarter of 2026 were $84
million, an increase of 28% compared to
the third quarter of 2025. In local currency terms revenues increased by 29%
mainly due to higher volumes.
COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38
million, a decrease of 12% compared
to the third quarter of 2025. In local currency terms revenues decreased by 11%,
mainly due to price reductions and lower volumes resulting
from the availability of alternative therapies.
Respiratory products revenues in our Europe segment in the third quarter of 2026
were $54 million, an increase of
3% compared to the third quarter of 2025. In local currency terms, revenues
increased by 4%, mainly due to higher volumes as a result
of increased supply.
Europe Gross Profit
Gross profitfrom our Europe segment in the third quarter of 2026 was $757
million, an increase of 14% compared to
the third quarter of 2025. Gross profit margin for our Europe segment in the
third quarter of 2026 increased to 57.4%,
compared to 53.9% in the third quarter of 2025. This increase was mainly due to
higher proceeds from the sale of certain product rights
and a positive impact from hedging activities.
Europe Profit
Profit from our Europe segment consists of revenues less cost of sales, R&D
expenses, S&M expenses, G&A expenses and other
expenses (income) related to this segment. Segment profit does not include
amortization and certain other items.
Profit from our Europe segment in the third quarter of 2026 was $420 million, an
increase of 39%, compared to the
third quarter of 2025. This increase was mainly due to higher gross profit, as
discussed above.
International Markets Segment
Our International Markets segment includes all countries in which we operate
other than the United States and the countries included
in our Europe segment. The International Markets segment covers a substantial
portion of the global pharmaceutical industry, including
more than 35 countries. The countries in our International Markets segment
include highly regulated, mainly generic markets, such as Canada
and Israel, and branded generics-oriented markets, such as Russia and certain
Latin America markets.
As of the date of this Quarterly Report on Form 10-Q, sustained conflict between
Russia and Ukraine and disruption in the region is
ongoing. Russia and Ukraine markets are included in our International Markets
segment results and we have no manufacturing or R&D
facilities in these markets. In September 2026, a warehouse that we share with
other pharmaceutical companies in Ukraine was damaged,
and, as of the date of this Quarterly Report on Form 10-Q, operations at this
warehouse resumed. The impact of this conflict on our International
Markets segment in the third quarter of 2026 was immaterial.
The following table presents revenues, expenses and profit for our International
Markets segment for the three months ended September
30, 2026 and 2025:
Three months ended
September 30,
2026
(U.S. $ in millions /
% of Segment
Revenues) 2025
──────────────────────────────────────────────────────────────────────────────
Revenues $ 592 100 % $ 557 100 %
Cost of sales 276 46.7 % 280 50.2 %
Gross profit 316 53.3 % 278 49.8 %
R&D expenses 31 5.3 % 26 4.6 %
S&M expenses 125 21.2 % 122 21.9 %
G&A expenses 34 5.7 % 36 6.4 %
Other § § § §
Segment profit* $ 125 21.1 % $ 95 17.0 %
_______________________
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.
Revenues from our International Markets segment in the third quarter of 2026
were $592 million, an increase of 6%
compared to the third quarter of 2025. In local currency terms, revenues
increased by 4% compared to the third quarter of 2025, mainly
due to higher revenues from our key innovative products AJOVY and AUSTEDO.
In the third quarter of 2026, revenues were positively impacted by exchange rate
fluctuations of $13 million, including hedging effects,
compared to the third quarter of 2025. Revenues in the third quarter of 2026
included $7 million from a positive hedging impact, compared
to $2 million in the third quarter of 2025, which are included in “Other” in the
table below.
Revenues by Major Products and Activities
The following table presents revenues for our International Markets segment by
major products and activities for the three months ended
September 30, 2026 and 2025:
Three months ended
September
30, Percentage
2026 Change
(U.S.$ in millions) 2025 2026-2025
──────────────────────────────────────────────────────────────────────────────
Generic products
(including OTC and $ 407 $ 421 (3)%
biosimilars)
AJOVY 48 30 61%
AUSTEDO 24 17 42%
COPAXONE 8 8 8%
Other* 105 82 28%
Total $ 592 $ 557 6%
_______________________*Other revenues in the third quarters of 2026 and 2025
include the sale of certain product
rights.
Generic products revenues (including OTC and biosimilar products) in our
International Markets segment in the third
quarter of 2026 were $407 million, a decrease of 3% compared to the third
quarter of 2025. In local currency terms, revenues decreased
by 4%, mainly due to lower revenues from generic and OTC products in certain
markets including Ukraine.
AJOVYrevenues in our International Markets segment in the third quarter of 2026
were $48 million, an increase of
61% in both U.S. dollars and local currency terms compared to the third quarter
of 2025. This increase was mainly due to growth in multiple
markets. In April 2026, we announced a strategic partnership for the marketing
and distribution of AJOVY in China with Nuerogen (Zhuhai)
Pharmaceutical Company Ltd.
AUSTEDOrevenues in our International Markets segment in the third quarter of
2026 were $24 million, an increase of
42% compared to the third quarter of 2025. In local currency terms, revenue
increased by 34% compared to the third quarter of 2025, mainly
due to growth in China.
COPAXONE revenues in our International Markets segment in the third quarter of
2026 were $8 million, an increase of
8% compared to the third quarter of 2025.
International Markets Gross Profit
Gross profit from our International Markets segment in the third quarter of 2026
was $316 million, an increase of
14% compared to the third quarter of 2025.
Gross profit margin for our International Markets segment in the third quarter
of 2026 increased to 53.3%, compared
to 49.8% in the third quarter of 2025. This increase was mainly due to a
favorable mix of products, primarily attributed to higher revenues
from AJOVY and AUSTEDO, partially offset by lower revenues from generic
products, as discussed above.
International Markets Profit
Profit from our International Markets segment consists of revenues less cost of
sales, R&D expenses, S&M expenses, G&A
expenses and other expenses (income) related to this segment. Segment profit
does not include amortization and certain other items.
Profitfrom our International Markets segment in the third quarter of 2026 was
$125 million, an increase of 32%, compared
to the third quarter of 2025. This increase was mainly due to higher gross
profit, as discussed above.
Other Activities
We have other sources of revenues, primarily our distribution business in the
United States to third parties through Anda, the sale
of APIs to third parties, an out-licensing platform offering a portfolio of
products to other pharmaceutical companies through our affiliate
Medis, and certain contract manufacturing services. Our Other Activities are not
included in our United States, Europe or International
Markets segments described above.
In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda
is no longer reported under our United States segment.
As a result, from that date, Anda is reported as part of our Other Activities.
Prior period amounts were recast to reflect this change.
In 2024, we announced that we intend to divest our API business (including its
R&D, manufacturing and commercial activities) through
a sale. The intention to divest is in alignment with our Pivot to Growth
strategy, and Teva is conducting a sales process for this matter.
However, there can be no assurance regarding the ultimate timing or structure of
a potential divestiture or that a divestiture will be
completed at all.
Our revenues from Other Activities in the third quarter of 2026 were $613
million, an increase of 3% in both U.S. dollars and local
currency terms, compared to the third quarter of 2025.
Anda revenues from third-party products in the third quarter of 2026 were $401
million, an increase of 2%, compared to the third quarter
of 2025, mainly due to higher volumes. Anda, our distribution business in the
United States, operates independently and distributes generic
and innovative medicines and OTC pharmaceutical products from various
manufacturers to independent retail pharmacies, pharmacy retail
chains, hospitals and physician offices in the United States. Anda competes in
the distribution market by maintaining a broad portfolio
of products, competitive pricing and delivery throughout the United States.
API sales to third parties in the third quarter of 2026 were $115 million, a
decrease of 8% in both U.S. dollars and local currency
terms, compared to the third quarter of 2025. This decrease was mainly due to
lower demand resulting from market dynamics and temporary
supply challenges.
Revenues from additional other activities, mainly from Medis and certain
contract manufacturing services, were $98 million in the third
quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency
terms compared to the third quarter of 2025, mainly due
to higher demand.
2026 Financial Outlook
$
billions, except Prior Updated Key
diluted EPS or as Guidance Guidance Assumptions
noted
Assume growth in
Revenues $16.5 - $16.85 $16.7 - $17.0 innovative
products
AUSTEDO ($m) 2,450 - 2,600 2,550 - 2,650
AJOVY ($m) 850 - 870 930 - 960
UZEDY ($m) 270 - 290 290 - 310
Increase of $0.05B
before updating
Operating Income* 3.8 - 4.0 3.8 - 3.9 guidance
for $0.1B impact of
acquired IPR&D
charge
Adjusted EBITDA* 4.23 - 4.53 4.23 - 4.43
Finance Expenses* ~$0.8 ~$0.8
Tax Rate* 20% - 23% 20% - 23%
Increase of $0.08 at
midpoint before
updating guidance
Diluted EPS* ($) 1.91 - 2.11 1.92 - 2.11 for
$0.07 impact of
acquired IPR&D
charge
Free Cash Flow* 2.0 - 2.4 2.1 - 2.4
CAPEX 0.5 0.5
Volatile swings in
Foreign Exchange FX can negatively
impact revenue and
income
Financial guidance only assumes business development transactions closed as of
November 3, 2026.
Certain items above are non-GAAP financial measures. For more information, see
“Non-GAAP Financial Measures”
below. Free Cash Flow includes cash flow generated from operating activities net
of capital expenditures and deferred purchase price cash
component collected for securitized trade receivables.
Conference Call
Teva will host a conference call and live webcast along with a slide
presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET
to discuss its third quarter 2026 financial results and overall business
environment.
A question & answer session will follow.
In order to participate, please register in advance to obtain a local or
toll‐free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at:
Following the conclusion of the call, a replay of the webcast will be available
within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a
leading innovative biopharmaceutical company, enabled
by a world-class generics business. For over 120 years, Teva’s commitment to
bettering health has never wavered. From innovating
in the fields of neuroscience and immunology to providing complex generic
medicines, biosimilars and pharmacy brands worldwide, Teva is
dedicated to addressing patients’ needs, now and in the future. At Teva, We Are
All In For Better Health. To learn more about how,
visit .
Some amounts in this press release may not add up due to rounding. All
percentages have been calculated using unrounded amounts.
Non-GAAP Financial Measures
This press release contains certain financial information that differs from what
is reported under accounting principles generally
accepted in the United States (“GAAP”). These non-GAAP financial measures,
including, but not limited to, non-GAAP operating
income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit
margin, Adjusted EBITDA, free cash flow, non-GAAP tax
rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS,
are presented in order to facilitate investors' understanding
of our business. We utilize certain non-GAAP financial measures to evaluate
performance in conjunction with other performance metrics.
The following are examples of how we utilize the non-GAAP measures: our
management and board of directors use the non-GAAP measures to
evaluate our operational performance and, to compare our results against work
plans and budgets, and ultimately to evaluate the performance
of management; our annual budgets are prepared on a non-GAAP basis; and senior
management’s annual compensation is derived, in part,
using these non-GAAP measures. See the attached tables for a reconciliation of
the GAAP results to the adjusted non-GAAP measures. Investors
should consider non-GAAP financial measures in addition to, and not as
replacements for, or superior to, measures of financial performance
prepared in accordance with GAAP. We are not providing the most comparable
forward-looking GAAP measures for non-GAAP metrics included
in our financial outlook or a quantitative reconciliation of forward-looking
non-GAAP financial measures to the most directly comparable
GAAP measures because we are unable to predict with reasonable certainty the
ultimate outcome of certain significant items including,
but not limited to, the amortization of purchased intangible assets, legal
settlements and loss contingencies, impairment of long-lived
assets and goodwill impairment, without unreasonable effort. These items are
uncertain, depend on various factors, and could be material
to our results computed in accordance with GAAP.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995,
which are based on management’s current beliefs and expectations and are subject
to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by
such forward-looking statements. You can identify these forward-looking
statements by the use of words such as “should,” "will",
“expect,” “aim”, “anticipate,” “estimate,” “target,” “may,” “project,”
“guidance,” “intend,” “plan,” “believe”, “outlook”, “transition”
and other words and terms of similar meaning and expression in connection with
any discussion of future operating financial performance
or development. Important factors that could cause or contribute to such
differences include risks relating to:
other factors discussed in this press release, in our Quarterly Report on Form
10-Q for the third quarter of 2026 and in our Annual
Report on Form 10-K for the year ended December 31, 2025, including in the
sections captioned “Risk Factors” and “Cautionary
Note Regarding Forward-Looking Statements.“ Forward-looking statements speak
only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking statements or other
information contained herein, whether as a result of
new information, future events or otherwise. You are cautioned not to put undue
reliance on these forward-looking statements.
Consolid…
Statemen…
of Income
(U.S.
dollars
in
millions,
except
share and
per share
data)
(Unaudit…
Three Nine
months months
ended ended
September September
30, 30,
2026 2025 2026 2025
Net $ 4,395 $ 4,480 $ 12,519 $ 12,547
revenues
Cost of 1,955 2,176 5,954 6,264
sales
Gross 2,440 2,304 6,565 6,282
profit
Research
and 297 256 1,489 746
developm…
expenses
Selling
and 709 656 2,122 1,933
marketing
expenses
General
and 298 317 919 920
administ…
expenses
Intangib…
assets 24 64 54 227
impairme…
Other
asset
impairme… 264 62 438 272
restruct…
and other
items
Legal
settleme… 202 60 504 312
and loss
continge…
Other
loss -68 7 -96 15
(income)
Operating
income 714 882 1,135 1,857
(loss)
Financial
expenses, 414 237 854 714
net
Income
(loss)
before 300 646 282 1,143
income
taxes
Income
taxes 66 214 254 210
(benefit)
Share in
(profits)
losses of * -2 * -4
associat…
companie…
net
Net
income 234 434 27 937
(loss)
Net
income
(loss)
attribut…
to 1 1 1 7
redeemab…
and
non-rede…
non-cont…
interest
Net
income
(loss) 233 433 26 930
attribut…
to Teva
Earnings
(loss)
per share Basic $ 0.20 $ 0.38 $ 0.02 $ 0.81
attribut…
to Teva:
Diluted $ 0.20 $ 0.37 $ 0.02 $ 0.80
Weighted
average
number of Basic 1,166 1,147 1,162 1,144
shares
(in
millions…
Diluted 1,183 1,164 1,180 1,160
Non-GAAP
net
income
attribut…
to Teva 1,013 910 1,655 2,281
for
diluted
earnings
per
share:**
Non-GAAP
earnings
per share Diluted $ 0.86 $ 0.78 $ 1.40 $ 1.97
attribut…
to
Teva:**
Non-GAAP
average
number of Diluted 1,183 1,164 1,180 1,160
shares
(in
millions…
Amounts
may not
add
up due to
rounding.
*
Represen…
an amount
less than
$0.5
million.
** See
reconcil…
attached.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in millions,
except for share data)
(Unaudited)
ASSETS September 30, December 31,
Current assets: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 4,085 $ 3,556
Accounts receivables, net of
allowance for credit losses
of $71 million and $81
million 3,837 3,709
as of September 30, 2026 and
December 31, 2025,
respectively.
Inventories 3,173 3,179
Prepaid expenses 1,014 1,122
Other current assets 658 539
Assets held for sale 1,836 1,842
Total current assets 14,602 13,946
Deferred income taxes 2,057 2,191
Other non-current assets 269 405
Property, plant and 3,747 4,080
equipment, net
Operating lease right-of-use 321 345
assets, net
Identifiable intangible 3,303 3,781
assets, net
Goodwill 15,742 16,000
Total assets $ 40,042 $ 40,748
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt $ 4,038 $ 1,820
Sales reserves and allowances 3,955 4,143
Accounts payables 2,551 2,531
Employee-related obligations 588 739
Accrued expenses 2,962 2,687
Other current liabilities 1,036 1,182
Liabilities held for sale 296 354
Total current liabilities 15,425 13,456
Long-term liabilities:
Deferred income taxes 263 296
Other taxes and long-term 3,422 3,808
liabilities
Senior notes and loans 12,680 14,986
Operating lease liabilities 266 288
Total long-term liabilities 16,632 19,379
Equity:
Teva shareholders’ equity: 7,979 7,910
Non-controlling interests 5 4
Total equity 7,984 7,914
Total liabilities and equity $ 40,042 $ 40,748
Amounts may not add up due to
rounding.
TEVA
PHARMACEUTI…
INDUSTRIES
LIMITED
CONSOLIDATED
STATEMENTS
OF CASH
FLOWS
(U.S.
dollars in
millions)
(Unaudited) Three months Nine months
Operating ended ended
activities: September 30, 2026 2025 September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 234 434 $ 27 937
(loss)
Adjustments
to reconcile
net income
(loss) to
net cash
provided by
operations:
Depreciation
and 245 249 725 742
amortization
Impairment
of
long-lived 228 79 350 255
assets and
assets held
for sale
Acquired
in-process 23 17 785 52
research and
development*
Net change
in operating -682 -578 -1,523 -1,647
assets and
liabilities
Deferred
income taxes
– net and 53 107 56 -76
uncertain
tax
positions
Stock-based 38 34 121 106
compensation
Loss on
extinguishm… 224 - 224 -
of debt
Other items -53 27 -65 122
Net loss
(gain) from
sale of
business -69 - -89 -
and
long-lived
assets
Net cash
provided by
(used in) 241 369 612 491
operating
activities
Investing
activities:
Beneficial
interest
collected in
exchange for 327 274 992 932
securitized
accounts
receivables
Purchases of
property,
plant and
equipment -120 -136 -393 -359
and
intangible
assets
Proceeds
from sale of
businesses 47 8 93 34
and
long-lived
assets, net
Purchases of
in-process -46 -12 -747 -41
research and
development*
Other
investing 2 1 3 6
activities
Net cash
provided by
(used in) 210 135 -52 572
investing
activities
Financing
activities:
Repayment of
senior notes
and loans
and -4,883 -444 -4,906 -4,112
other
long-term
liabilities
Proceeds
from senior
notes, net 4,845 -7 4,845 2,298
of
issuance
costs
Purchase of
shares from
redeemable
and - - - -38
non-redeema…
non-control…
interests
Dividends
paid to
redeemable
and - - - -340
non-redeema…
non-control…
interests
Other
financing 43 -2 78 1
activities
Net cash
provided by
(used in) 6 -453 18 -2,191
financing
activities
Effect of
exchange
rate changes -27 -9 -49 31
on cash
and cash
equivalents
Net change
in cash and 430 42 529 -1,097
cash
equivalents
Balance of
cash and
cash
equivalents 3,655 2,161 $ 3,556 3,300
at
beginning of
period
Balance of
cash and
cash
equivalents $ 4,085 2,203 $ 4,085 2,203
at
end of
period
Non-cash
financing
and
investing
activities:
Beneficial
interest
obtained in
exchange $ 253 296 $ 859 937
for
securitized
accounts
receivables
Receivable
for sale of 90 - 90 -
long-lived
assets
* In the
first nine
months of
2026, mainly
related to
the
acquisition
of Emalex
and its
primary
asset
ecopipam
(EBS-101).
Amounts may
not add up
due to
rounding.
The
accompanying
notes are an
integral
part of the
financial
statements.
($ in
millions
except per
share
amounts)
Net income
(Loss)
attributable
to Teva
Increase
(decrease)
for excluded
items:
Amortization
of purchased
intangible
assets
Legal
settlements
and loss
contingenci…
Impairment
of
long-lived
assets(2)
Restructuri…
costs(3)
Equity
compensation Three
Contingent months Nine months
considerati… ended ended
Financial September September
expenses(4) 30, 30,
Other 2026 2025 2026 2025
Reconcilia… non-GAAP 233 433 26 930
of net items(5) 139 144 415 436
income Correspondi… 201 60 503 309
(loss) tax effects 228 79 350 255
attributab… and unusual 58 29 121 196
to Teva tax items(6) 38 34 121 106
to Non-GAAP Non-GAAP net 2 16 25 46
net income income 235 7 256 58
(loss) attributable 14 51 55 170
attributab… to Teva (134) 58 (216) (225)
to Teva Non-GAAP tax 1,013 910 1,655 2,281
(Unaudited) rate(7) 16.5 % 14.7 % 22.1 % 16.0 %
──────────────────────────────────────────────────────────────────────────────
GAAP diluted
earnings
(loss) per $ 0.20 0.37 $ 0.02 0.80
share
attributable
to Teva
EPS 0.66 0.41 1.38 1.16
difference(…
Non-GAAP
diluted EPS $ 0.86 0.78 $ 1.40 1.97
attributable
to Teva(8)
Non-GAAP
average
number of 1,183 1,164 1,180 1,160
shares (in
millions)(8)
For the
three months
ended
September
30, 2026,
adjustments
for legal
settlements
and loss
contingenci…
mainly
consisted of
(a) an
update to
the
estimated
provision
recorded in
connection
with one of
the
Company’s
ongoing
antitrust
litigations
in the
amount of
$133
million, and
(b) an
update to
the
estimated
settlement
provision
for the
opioid
cases
(mainly the
effect of
the passage
of time on
the net
present
value of the
discounted
payments) in
the amount
of $35
million.
For the nine
months ended
September
30, 2026,
adjustments
for legal
settlements
and loss
contingenci…
mainly
consisted of
(a) an
estimated
provision
recorded in
connection
with one of
the
Company’s
ongoing
antitrust
litigations
in the
amount of
$250
million, and
(b)
(1) an update to
the
estimated
settlement
provision
for the
opioid cases
(mainly the
effect of
the passage
of time on
the net
present
value
of the
discounted
payments) in
the amount
of $132
million. For
the three
and nine
months ended
September
30, 2025,
adjustments
of
legal
settlements
and loss
contingenci…
mainly
consisted of
(a) an
update to
the
estimated
settlement
provision
for the
opioid cases
(mainly the
effect of
the passage
of time on
the net
present
value of the
discounted
payments) in
the amount
of $42
million and
$139
million,
respectivel…
and (b) an
update to
the
estimated
provision
recorded for
the claims
brought by
attorneys
general
representing
states and
territories
throughout
the U.S. in
the generic
drug
antitrust
litigation
in the
amount of
$55 million.
The expense
for the
three and
nine months
ended
September
30, 2026,
mainly
consisted of
(a)
impairment
charges in
connection
with several
manufacturi…
facilities
in Europe in
the amount
of $140
million and
$210
million,
respectivel…
and (b)
impairment
charges in
connection
with the
held for
sale
measurement
of the API
business
(including
its R&D,
manufacturi…
(2) and
commercial
activities),
which
includes an
impact
related to
the expected
gain from
reclassific…
of
currency
translation
adjustments
in the
amount of
$49 million
and $66
million,
respectivel…
For the nine
months ended
September
30, 2025,
the
adjustment
for
impairment
of
long-lived
assets was
mainly
related to
intangible
assets in
the U.S. and
Europe.
In the nine
months ended
September
30, 2026 and
2025, Teva
recorded
restructuri…
expenses of
$121 million
and $196
million,
respectivel…
primarily
related to
optimization
(3) activities
in
connection
with Teva’s
Transformat…
programs
related to
Teva’s
global
organization
and
operations
mainly
through
headcount
reduction.
In the three
and nine
months ended
September
30, 2026,
Teva
recorded
(4) $224
million of
finance
expenses
related to a
loss on
extinguishm…
of debt.
Other
non-GAAP
items
include
other
exceptional
items that
we believe
are
sufficiently
large that
their
exclusion is
important to
facilitate
an
(5) understandi…
of trends in
our
financial
results,
primarily
related
to material
litigation
fees,
rationaliza…
of our
plants,
accelerated
depreciation
and other
unusual
events.
Adjustments
for
correspondi…
tax effects
and unusual
tax items
exclusively
consisted of
the tax
impact
directly
(6) attributable
to the
pre-tax
items that
are excluded
from
non-GAAP net
income
included in
the other
adjustments
to this
table.
Non-GAAP tax
rate is tax
expenses
(benefit)
excluding
the impact
of non-GAAP
tax
adjustments
presented
above as a
percentage
of income
(loss)
before
income taxes
excluding
the impact
of non-GAAP
adjustments
presented
above. Our
non-GAAP tax
rate in the
nine months
ended
September
30, 2026 was
mainly
affected by
an
unfavorable
tax impact
(7) of a
non-deducti…
acquired
IPR&D charge
related to
the
acquisition
of Emalex
and its
primary
asset
ecopipam
(EBS-101),
the
generation
of profits
in
various
jurisdictio…
in which tax
rates are
different
than the
Israeli tax
rate, and
other
infrequent
or
non-recurri…
items, such
as
internal
legal
entities
reorganizat…
EPS
difference
and diluted
non-GAAP EPS
are
calculated
by dividing
our
(8) non-GAAP net
income
attributable
to Teva by
our non-GAAP
diluted
weighted
average
number of
shares.
Reconciliation
of gross profit
to
Non-GAAP gross
profit
(Unaudited)
Three months Nine months ended
ended
September 30, September 30,
($ in millions) 2026 2025 2026 2025
Gross profit $ 2,440 2,304 $ 6,565 6,282
Gross profit 55.5% 51.4% 52.4% 50.1%
margin
Increase
(decrease) for
excluded items:
(1)
Amortization of
purchased 129 134 387 406
intangible
assets
Equity 6 6 18 17
compensation
Other non-GAAP 5 32 11 101
items
Non-GAAP gross $ 2,580 2,475 $ 6,981 6,807
profit
Non-GAAP gross
profit margin 58.7% 55.3% 55.8% 54.3%
(2)
(1) For further
explanations,
refer to the
footnotes under
the
"Reconciliation
of net income
(loss)
attributable to
Teva to Non-GAAP
net income
(loss)
attributable to
Teva" table.
(2) Non-GAAP
gross profit
margin is
non-GAAP gross
profit as a
percentage
of revenue.
Reconciliation
of operating
income (loss)
to Non-GAAP
operating
income (loss)
(Unaudited)
Three months Nine months
ended ended
September 30, September 30,
($ in millions) 2026 2025 2026 2025
Operating $ 714 882 $ 1,135 1,857
income (loss)
Operating 16.2 % 19.7 % 9.1 % 14.8 %
margin
Increase
(decrease) for
excluded items:
(1)
Amortization of
purchased 139 144 415 436
intangible
assets
Legal
settlements and 201 60 503 309
loss
contingencies
Impairment of
long-lived 228 79 350 255
assets
Restructuring 58 29 121 196
costs
Equity 38 34 121 106
compensation
Contingent 2 16 25 46
consideration
Loss (gain) on
sale of -1 6 -5 19
business
Other non-GAAP 15 45 60 149
items
Non-GAAP
operating $ 1,393 1,294 $ 2,724 3,373
income (loss)
Non-GAAP
operating 31.7 % 28.9 % 21.8 % 26.9 %
margin(2)
(1) For further
explanations,
refer to the
footnotes under
the
"Reconciliation
of net income
(loss)
attributable to
Teva to
Non-GAAP net
income (loss)
attributable to
Teva" table.
(2) Non-GAAP
operating
margin is
Non-GAAP
operating
income
as a percentage
of revenues.
Reconcilia…
of net
income
(loss) to
adjusted
EBITDA
(Unaudited)
Three months Nine months
ended ended
September 30, September
30,
($ in 2026 2025 2026 2025
millions)
Net income $ 234 434 $ 27 937
(loss)
Increase
(decrease)
for
excluded
items:(1)
Financial 414 237 854 714
expenses
Income taxes 66 214 254 210
Share in
profits
(losses) of § -2 § -4
associated
companies
–net
Depreciation 106 105 311 306
Amortization 139 144 415 436
EBITDA 959 1,131 1,861 2,599
Legal
settlements 201 60 503 309
and loss
contingenci…
Impairment
of long 228 79 350 255
lived assets
Restructuri… 58 29 121 196
costs
Equity 38 34 121 106
compensation
Contingent 2 16 25 46
considerati…
Loss (Gain)
on sale of -1 6 -5 19
Business
Other
non-GAAP 12 40 50 137
items
Adjusted $ 1,496 1,394 $ 3,025 3,668
EBITDA
(1) For
further
explanatio…
refer to
the
footnotes
under
the
"Reconcili…
of net
income
(loss)
attributab…
to Teva to
Non-GAAP
net income
(loss)
attributab…
to Teva"
table.
§
Represents
an amount
of less
than $0.5
million.
U… In…
S… E… Ma…
T… T… Th…
m… m… mo…
e… e… en…
S… S… Se…
3… 3… 30,
2… 2… 20…
(… (… (U…
… $ $ $
… in in in
… m… 2… m… 2… mi… 20…
──────────────────────────────────────────────────────────────────────────────
… $ 1… $ 2… $ 1… $ 1… $ 5… $ 5…
…
… 4… 6… 5… 5… 2… 2…
…
… 1… 1… 7… 6… 3… 2…
…
… 1… 1… 62 62 31 26
…
… 3… 2… 2… 2… 1… 1…
…
… 1… 1… 64 75 34 36
…
… § -3 § § § §
… $ 7… $ 9… $ 4… $ 3… $ 1… $ 95
…
*
…
…
…
…
…
…
…
…
…
…
§
…
…
…
…
…
…
…
Un…
St… Int…
Ni… Eur… Mar…
mo… Nine Nine
en… mon… mon…
Se… end… end…
30, Sep… Sep…
20… 30, 30,
(U… 2026 2026
S… $ (U.… (U.…
I… in $ in $ in
U… mi… 20… mil… 2025 mil… 2025
──────────────────────────────────────────────────────────────────────────────
R… $ 5,… $ 5,… $ 3,… $ 3,… $ 1,… $ 1,…
C…
of 1,… 1,… 1,… 1,… 823 835
s…
G… 3,… 3,… 2,… 2,… 843 799
p…
R… 1,… 467 159 181 80 75
e…
S… 898 741 648 652 370 353
e…
G… 307 319 203 210 111 107
e…
O… -9 -1 -3 § -8 -3
i…
S… $ 1,… $ 2,… $ 1,… $ 996 $ 289 $ 266
p…
*
S…
p…
d…
n…
i…
a…
a…
c…
o…
i…
§
R…
an
a…
l…
t…
$…
m…
Reconciliation of our segment profit Three months ended
to consolidated income (loss) before September 30,
income taxes (U.S.$ in millions) 2026 2025
──────────────────────────────────────────────────────────────────────────────
United States profit $ 791 $ 927
Europe profit 420 303
International Markets profit 125 95
Total reportable segment profit 1,336 1,325
Profit (loss) of other activities 57 -31
Amounts not allocated to segments:
Amortization 139 144
Other asset impairments,
restructuring 264 62
and other items
Intangible asset impairments 24 64
Legal settlements and loss 201 60
contingencies
Other unallocated amounts 51 82
Consolidated operating income (loss) 714 882
Financial expenses - net 414 237
Consolidated income (loss) before
income $ 300 $ 646
taxes
Nine months ended
Reconciliation of our September 30,
segment profit September 30,
to consolidated income 2026
(loss) before income taxes (U.S.$ in millions) 2025
──────────────────────────────────────────────────────────────────────────────
United States profit $ 1,222 $ 2,143
Europe profit 1,188 996
International Markets 289 266
profit
Total reportable segment 2,699 3,405
profit
Profit (loss) of other 25 -32
activities
Amounts not allocated to
segments:
Amortization 415 436
Other asset impairments,
restructuring 438 272
and other items
Intangible asset 54 227
impairments
Legal settlements and loss 503 309
contingencies
Other unallocated amounts 179 272
Consolidated operating 1,135 1,857
income (loss)
Financial expenses - net 854 714
Consolidated income (loss)
before income $ 282 $ 1,143
taxes
Segment revenues by
major products and
activities Three months ended
(Unaudited) September 30, Percentage
United States 2026 Change
segment (U.S.$ in millions) 2025 2026-2025
──────────────────────────────────────────────────────────────────────────────
Generic products
(including $ 718 $ 1,175 (39)%
biosimilars)
AJOVY 138 73 88 %
AUSTEDO 727 601 21 %
BENDEKA and TREANDA 30 35 (15)%
COPAXONE 58 62 (8)%
UZEDY 85 43 96 %
Other 114 101 13 %
Total 1,870 2,090 (11)%
Three months ended Percentage
September 30, Change
2026 2025 2026-2025
-U.S.$ in millions
Europe segment
Generic products
(including OTC and $ 1,033 $ 982 5 %
biosimilars)
AJOVY 84 66 28 %
COPAXONE 38 44 (12)%
Respiratory 54 52 3 %
products
Other* 111 91 21 %
Total 1,319 1,235 7 %
*Other revenues in
the third quarter
of 2026 and 2025
include the sale
of certain product
rights
Three months ended Percentage
September 30, Change
2026 2025 2026-2025
-U.S.$ in millions
International
Markets segment
Generic products
(including OTC and $ 407 $ 421 (3)%
biosimilars)
AJOVY 48 30 61 %
AUSTEDO 24 17 42 %
COPAXONE 8 8 8 %
Other* 105 82 28 %
Total 592 557 6 %
*Other revenues in
the third quarter
of 2026 and 2025
include the sale
of certain product
rights
Segment
revenues by
major products Nine months ended
and activities September 30,
(Unaudited) 2026 Percentage
United States (U.S.$ in Change
segment millions) 2025 2025-2026
──────────────────────────────────────────────────────────────────────────────
Generic $ 1,990 $ 2,984 (33)%
products
AJOVY 341 190 80 %
AUSTEDO 1,963 1,492 32 %
BENDEKA / 85 111 (24)%
TREANDA
COPAXONE 182 179 2 %
UZEDY 225 136 65 %
Other 321 321 §
Total 5,106 5,413 (6)%
§ Represents an
amount less
than 0.5%.
Nine months ended
September 30, Percentage
Change
2026 2025 2025-2026
-U.S.$ in
millions
Europe segment
Generic $ 3,146 $ 3,011 4 %
products
AJOVY 238 195 22 %
COPAXONE 127 135 (6)%
Respiratory 171 162 6 %
products
Other* 241 223 8 %
Total 3,922 3,726 5 %
*Other revenues
in the first
nine months of
2026 and 2025
include the
sale of certain
product rights.
Nine months ended
September 30, Percentage
Change
2026 2025 2025-2026
-U.S.$ in
millions
International
Markets segment
Generic $ 1,212 $ 1,298 (7)%
products
AJOVY 130 78 68 %
AUSTEDO 63 34 82 %
COPAXONE 22 25 (13)%
Other* 239 199 20 %
Total 1,666 1,634 2 %
*Other revenues
in the first
nine months of
2026 and 2025
include the
sale of certain
product rights.
Free cash flow
reconciliation
(Unaudited)
Three months ended
September
30,
2026 2025
-U.S. $ in millions
Net cash provided by
(used in) operating 241 369
activities
Beneficial interest
collected in
exchange for 327 274
securitized account
receivables
Capital investment -120 -136
Proceeds from sale of
businesses and 47 8
long-lived assets,
net
Free cash flow $ 495 $ 515
Free cash flow
reconciliation
(Unaudited)
Nine months ended
September
30,
2026 2025
-U.S. $ in millions
Net cash provided by (used
in) operating 612 491
activities
Beneficial interest
collected in
exchange for securitized 992 932
trade
receivables
Capital investment -393 -359
Proceeds from sale of
businesses and 93 34
long-lived assets, net
Free cash flow $ 1,305 $ 1,098
Net debt reconciliation
unaudited
September 30,
2026
Short-term debt 4,038
Senior notes and loans 12,680
Total debt 16,718
Net of cash and cash equivalents 4,085
Net debt $ 12,633
Teva Media Inquiries: [email protected]
Teva Investor Relations Inquiries: [email protected]